AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Eli Lilly Plunges 12.91% on Trump's 250% Tariff Threat
Generated by AI AgentAinvest Pre-Market Radar
Thursday, Aug 7, 2025 6:44 am ET1min read
Aime SummaryOn August 7, 2025, Eli Lilly's stock experienced a significant drop of 12.91% in pre-market trading.
President Donald Trump's announcement of a potential 250% tariff on pharmaceutical imports has sent shockwaves through the industry, with Eli Lilly's stock price taking a notable hit. This move by the Trump administration has raised concerns about the financial impact on pharmaceutical companies, including
, which relies heavily on international trade.Eli Lilly's recent clinical trial results for its oral GLP-1 drug, orforglipron, have shown promising weight loss outcomes, with an average loss of 27.3 pounds in the first of two pivotal Phase 3 trials. However, the stock's performance has been overshadowed by the tariff threat, which has overshadowed the positive news from the clinical trials.
Despite the recent setbacks, Eli Lilly continues to focus on its core strengths in diabetes, oncology, immunology, and neuroscience. The company's ongoing research and development efforts are expected to drive future growth, although the current market volatility poses a challenge.
Ainvest Pre-Market Radar
Get the scoop on pre-market movers and shakers in the US stock market.
Latest Articles
Getty Images (NYSE:GETY) surges 5.51% on renewed investor confidence
Jan.02 2026
Olaplex Holdings (NASDAQ: OLPX) shares plunged 7.59% on mixed analyst outlooks and shifting institutional positioning.
Jan.02 2026
The Real Brokerage shares surge 7.04% on Jan. 2 2026 driven by regulatory tailwinds and restructuring optimism
Jan.02 2026
Vanda Pharmaceuticals shares surged 25.46% on partnership and FDA Breakthrough Therapy Designation.
Jan.02 2026
Vanda Pharmaceuticals shares surge 25.46% on partnership and FDA breakthrough designation
Jan.02 2026
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet